this is an 8 kid study, not material. More important, I noticed that Eisai hired an experienced and talented senior level marketing pro from Sanofi for Belviq. Hopefully, she can get this turned around, if she has the budget.
is this a surprise? Of course it's going to take some time and more insurance coverage for a significant rise in volume. I have been saying that for months, which is why I have been selling calls against my stock. Eventually I think EXAS will be acquired for $30-40+. I can be patient and trade around the core position. You don't have to be a Goldman analyst to know launching a new product for a new market takes time.
When they need to raise money, or sell their personal stock, they over-promise and then they don't deliver... Nice recent sale by ARNA's corp council Spector at $5. Did he know the promised clinical info would not be delivered on time as promised. Getting tired of ARNA execs winning and shareholders losing. This must change! Glad I own some oil stocks today, bios not so good.
did you say break out, or break down. This stock and the shareholders can't catch a break. Spector sold at $5. Every insider sales seems to mark a ST top. At least they are good at something!
I am a buyer at $19-20 if that ever happens. I am surprised it held up in the $30's after another delay. Insiders have been selling for the past 2 years. Maybe this forces them to sell the company, but then the question is what's the fair price?
If you don't agree, buy some stock and take advantage. It's a strange call at this point in time with crude starting to show signs of stability and with the company well hedged until the end of 2016. I am tempted to add a little.
Amen to all of these posts, now what? We all know JL is not qualified to be CEO of a commercial company, or any company, he's a weak leader and not worth what he's being paid. We all know the BOD is bought and paid for by JL and co. Unless you can find an activist, or large shareholder that wants Jack out, we are stuck with his stupid #$%$.
Now we can decide to wait for another product in the pipeline, or sell and move on. Eisai is a conservative + weak/marginal commercial organization. Eisai has other strong pipeline activity and therefore not likely interested aggressively developing Bel for other indications and/or investing heavily in marketing for obesity.
In summary, the pipeline is our only hope for this stock making a run to the area where longs can make a reasonable profit for their long suffering, high risk. Until something happens, shorts/hedgies are in control selling at $5 and buying under $4. This is not a good growth investment situation, it may be a value play, or a value trap. We will know in less than another year when they will need to dilute again if there's no acquisition.
Another flushing just because they can I guess and to strike fear on the long psychology. We just need some pipeline progress to put an end to this manipulation and get the shorts buying, covering and leaving.
Amen, but it's really not a big deal seeing the MD and getting a refill every 5-6 months. If someone is on a weight loss med, or other med I would think they are seeing their doc at least this frequently. Also, most MD's will refill over the phone. I take Humira and see the MD about 2x a year for a brief review.
interesting, thanks. I figured it was the Japan ETF trade, or something that was market related and had nothing to do with the carpy company Eisai. Maybe they just can't market and sell. Imaging Belviq in the hands of a marketing powerhouse? No more deals with Eisai.
agree, over the next 9-12 months assuming the insurance co's continue to add the product to their list.